JP2023541827A - Ｇｌｐ－１受容体アゴニストの改善された医薬製剤 - Google Patents

Ｇｌｐ－１受容体アゴニストの改善された医薬製剤 Download PDF

Info

Publication number
JP2023541827A
JP2023541827A JP2023515289A JP2023515289A JP2023541827A JP 2023541827 A JP2023541827 A JP 2023541827A JP 2023515289 A JP2023515289 A JP 2023515289A JP 2023515289 A JP2023515289 A JP 2023515289A JP 2023541827 A JP2023541827 A JP 2023541827A
Authority
JP
Japan
Prior art keywords
copolymer
coating
mol
repeat units
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541827A5 (enExample
Inventor
フロリアン フェーガー，
マルティン ヴェルレ，
Original Assignee
サイプルメド ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイプルメド ゲーエムベーハー filed Critical サイプルメド ゲーエムベーハー
Publication of JP2023541827A publication Critical patent/JP2023541827A/ja
Publication of JP2023541827A5 publication Critical patent/JP2023541827A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023515289A 2020-09-07 2021-09-07 Ｇｌｐ－１受容体アゴニストの改善された医薬製剤 Pending JP2023541827A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20194828 2020-09-07
EP20194828.8 2020-09-07
EP20208628 2020-11-19
EP20208628.6 2020-11-19
PCT/EP2021/074625 WO2022049310A1 (en) 2020-09-07 2021-09-07 Improved pharmaceutical formulations of glp-1 receptor agonists

Publications (2)

Publication Number Publication Date
JP2023541827A true JP2023541827A (ja) 2023-10-04
JP2023541827A5 JP2023541827A5 (enExample) 2024-09-13

Family

ID=77821779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515289A Pending JP2023541827A (ja) 2020-09-07 2021-09-07 Ｇｌｐ－１受容体アゴニストの改善された医薬製剤

Country Status (5)

Country Link
US (1) US20240041983A1 (enExample)
EP (1) EP4210680A1 (enExample)
JP (1) JP2023541827A (enExample)
CN (1) CN116419750A (enExample)
WO (1) WO2022049310A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CA3237751A1 (en) 2021-11-10 2023-05-19 Tyler Brown Ionic liquid compositions
WO2023166179A1 (en) * 2022-03-03 2023-09-07 Cyprumed Gmbh Improved oral pharmaceutical formulations of therapeutic peptides and proteins
TW202400219A (zh) * 2022-04-29 2024-01-01 香港商鵬躍醫藥科技有限公司 用於鼻內給藥的索馬魯肽及其鹽的藥物組合物
KR20250057847A (ko) 2022-08-29 2025-04-29 일라이 릴리 앤드 캄파니 경구 전달용 조성물
WO2024134493A1 (en) * 2022-12-19 2024-06-27 Quisitive Therapeutics Drug delivery system for tirzepatide
US12605427B2 (en) * 2023-05-15 2026-04-21 Red Mountain Med Spa, LLC Sublingual semaglutide-BPC 157 combination for weight loss
CN122376711A (zh) * 2024-06-03 2026-07-14 深圳奥礼生物科技有限公司 口服的多肽组合物
WO2026084427A1 (ko) * 2024-10-16 2026-04-23 국민대학교산학협력단 세마글루티드 및 흡수촉진제를 유효성분으로 포함하는 경구투여용 제제 및 이의 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533656A (ja) * 2011-11-30 2014-12-15 武田薬品工業株式会社 有核錠
JP2016500682A (ja) * 2012-10-17 2016-01-14 ノヴォ ノルディスク アー／エス 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸
JP2018505172A (ja) * 2015-01-29 2018-02-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト及び腸溶コーティングを含む錠剤
US20200237875A1 (en) * 2019-01-30 2020-07-30 Synlev Pharmaceuticals Corporation Formulations and methods for treatment of fibromyalgia and related myofascial pain disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE69916811T2 (de) 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ 新規なｇｌｐ−１化合物
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
ES2484796T3 (es) 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
AU2010250452B2 (en) 2009-05-20 2014-06-05 Toray Industries, Inc. Cell membrane-permeable peptides
CN102596253B (zh) 2009-09-30 2013-11-06 蒂奥迈里克斯研究与指导有限公司 含有维生素b 亚结构的粘膜粘着聚合物
KR20130100897A (ko) 2010-04-21 2013-09-12 나노메가 메디컬 코포레이션 나노입자의 약제학적 조성물
WO2012112319A1 (en) 2011-02-04 2012-08-23 Aegis Therapeutics, Llc Orally bioavailable peptide drug compositions and methods thereof
CN103458873B (zh) 2011-04-14 2016-04-13 诺沃—诺迪斯克有限公司 用于口服肽递送的脂肪酸酰化的氨基酸
CA2872314C (en) 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
US20150174076A1 (en) 2012-06-14 2015-06-25 Entrega, Inc. Mucoadhesive devices for delivery of active agents
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
CN105832691B (zh) * 2016-05-31 2018-10-02 深圳市健元医药科技有限公司 一种度拉糖肽结肠定位缓释制剂及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533656A (ja) * 2011-11-30 2014-12-15 武田薬品工業株式会社 有核錠
JP2016500682A (ja) * 2012-10-17 2016-01-14 ノヴォ ノルディスク アー／エス 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸
JP2018505172A (ja) * 2015-01-29 2018-02-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト及び腸溶コーティングを含む錠剤
US20200237875A1 (en) * 2019-01-30 2020-07-30 Synlev Pharmaceuticals Corporation Formulations and methods for treatment of fibromyalgia and related myofascial pain disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AAPS PHARMASCI, vol. 3, no. 2, JPN6025041297, 2001, pages 14, ISSN: 0005920712 *
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 357, JPN6026032161, 2008, pages 219 - 227, ISSN: 0005920714 *
粉砕, JPN6025041299, 2006, pages 3 - 10, ISSN: 0005920713 *

Also Published As

Publication number Publication date
CN116419750A (zh) 2023-07-11
WO2022049310A1 (en) 2022-03-10
EP4210680A1 (en) 2023-07-19
US20240041983A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
US20240041983A1 (en) Improved pharmaceutical formulations of glp-1 receptor agonists
US10905744B2 (en) Pharmaceutical formulations for the oral delivery of peptide drugs
Shaji et al. Protein and peptide drug delivery: oral approaches
CN101801309B (zh) 口服递送的肽药物
EP1791553B1 (en) Compositions for delivering peptide yy and pyy agonists
US20170304195A1 (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs
KR102294577B1 (ko) 고체 경구 제형
US20090304768A1 (en) Gastro-Retentive System for the Delivery of Macromolecules
BRPI0908292B1 (pt) Métodos e composições para administração oral de exenatida
KR19990087798A (ko) 경구용 펩티드 의약품
CN110662550A (zh) 生理活性物质的口服给药
KR20250141711A (ko) 경구 투여되는 폴리펩타이드 치료제의 전신 생체이용률을 증가시키는 조성물 및 방법
JP2025508982A (ja) 治療用ペプチドおよびタンパク質の改善された経口医薬製剤
EP4026566B1 (en) Oral pharmaceutical composition comprising teriparatide and method for preparing same
WO2016004067A1 (en) Aromatic-cationic peptide formulations, compositions and methods of use
JP2022522550A (ja) 副甲状腺ホルモンアナログの経口製剤および治療
Yoshida et al. Oral drug delivery systems applied to launched products: Value for the patients and industrial considerations
WO2017168245A1 (en) Pharmaceutical compositions and methods for the treatment of diabetes
US20220323544A1 (en) Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP2012111773A (ja) 経口吸収改善用医薬組成物
EP3999637B1 (en) Intestinal alkaline phosphatase-based treatments of metabolic disorders
EP1300155A1 (en) Enteric preparations containing physiologically active peptides
WO2025112258A1 (zh) 一种实现多肽口服吸收的组合物
CA3238277A1 (en) Oral dosage forms
Hill Pharmacokinetic analysis and formulation development of therapeutic proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260731